Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

BERWYN, Pa., Oct. 19 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.

Prior to the transaction, the Company has entered into Warrant Exchange Agreements with two investors (the "Investors") pursuant to which the Company issued to the Investors an aggregate of 1,864,000 shares of Common Stock (collectively, the "Exchange Shares") and warrants to purchase an aggregate of 874,126 shares of Common Stock, exercisable for a period of five years, at an exercise price of $.40 per share (collectively, the "Exchange Warrants"). The Exchange Shares and Exchange Warrants were issued in exchange for warrants dated as of May 9, 2007 held by the Investors to purchase an aggregate of 874,126 shares of Common Stock of the Company (collectively, the "Original Warrants").

The Company also announced that it has terminated previously announced negotiations for the sale of the Company's wholly-owned subsidiary Encorium OY to a clinical research organization based in the United States and will not pursue a sale of the Company or Encorium OY at this time. Given the Company's recent successes with respect to its strategy to grow into the world's leading vaccine franchise, including the recently announced $8.7 million of new business contract wins and the selection by a major pharmaceutical company for participation in a swine flu vaccine program, together with the investment announced today, the Company believes it is well
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech (Cayman) ... capability and technology platform company serving the pharmaceutical, biotechnology, ... ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), a ... with 20 years of operations in ... companies have signed an agreement whereby WuXi,s Laboratory Testing ...
(Date:8/25/2015)... ... 2015 , ... One of the world’s foremost authorities on supply chain risk ... been on a mission for the past two weeks. She’s been scrambling to warn ... the two massive explosions that occurred on August 12 at the Ruihai International Logistics ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... and PARSIPPANY, N.J., May 12 Forest,Laboratories, ... pharmaceutical company, and,Daiichi Sankyo, Inc. today announced ... AZOR(TM)* (amlodipine and olmesartan medoxomil),Daiichi Sankyo,s fixed-dose ... amlodipine besylate and the angiotensin receptor,blocker olmesartan ...
... elution technology to ... reduce and sustain intraocular pressure, VANCOUVER, May 12 ... results from a proof of concept trial conducted by,QLT,s ... plug,drug delivery technology. The results demonstrated that QLT,s drug ...
... WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading ... stem cell research systems,today announced that Mr. Alnoor ... corporate presentation at the Rodman & Renshaw,Fifth Annual ... May,19-20, 2008, at the Le Meridien Beach Plaza ...
Cached Biology Technology:Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 2Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 3Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 4QLT reports initial proof of concept data for punctal plug delivery technology 2QLT reports initial proof of concept data for punctal plug delivery technology 3QLT reports initial proof of concept data for punctal plug delivery technology 4WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference 2
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/4/2015)... , Aug. 04, 2015 ... http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition of ... (Hardware, Software, and Service), Sub-Segment (Computer Forensics, ... Forensics), Tool Types, Service, Vertical and Region ... to their offering. By Component ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... big effect on their life. Some people are outgoing ... can be detrimental to their health and wellbeing. Increasingly, ... , A new study led by Dr Kathryn Arnold, ... has added important experimental evidence showing that animal personalities ...
... NY, April 27, 2011An international team of scientists, led by ... has used DNA to determine that groups of dusky ... brachyurus ) living in different coastal regions across the globe ... predators that are heavily exploited for the shark fin trade, ...
... PHILADELPHIA A Philadelphia botanist who has studied rare plants for ... plant named for him is finally getting his due, but with ... again. Dr. Alfred "Ernie" Schuyler, emeritus curator of botany ... rare plants, recently was honored when a colleague discovered a new ...
Cached Biology News:Animals have personalities, too 2Scientists can track origin of shark fins using 'zip codes' in their DNA 2Scientists can track origin of shark fins using 'zip codes' in their DNA 3Rare Pennsylvania fungus is named for Philadelphia botanist 2
MpV17 transgene, murine homolog, glomerulosclerosis...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
8.1.1...
Biology Products: